Skip to main content
Premium Trial:

Request an Annual Quote

Big Names Weigh In

While personal genomics companies say their tests have predictive value and will be helpful in health and wellness, The Economist asks what David Altshuler, Craig Venter, Russ Altman, George Church, and others think. Altshuler says that companies encourage people to read too deeply into their genomes -- he refused to have his sequenced -- and that he's worried about a backlash. And though Venter wants to sequence everyone's genomes, he cautions that "we don't yet know which parts of the genome are medically relevant." Altman, however, says that genomics has potential for developing pharmaceuticals, but that pharma companies are dragging their feet. Church adds that whole-genome sequencing in the future will be offered by companies nearly for free as they use it to sell other services.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.